Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	28.09	28.16	71.44	69.49	1.01
Short-Term Investments	60.04	91.6	0	24.49	0
Cash & Cash Equivalents	88.13	119.77	71.44	93.98	1.01
Cash Growth	-26.42%	67.66%	-23.99%	9213.88%	-99.15%
Other Current Assets	2.05	0.97	0.77	3.98	3.74
Total Current Assets	90.18	120.74	72.2	97.95	4.75
Property, Plant & Equipment	3.76	3.69	4.46	4.98	0.36
Other Long-Term Assets	2	1.98	2.01	1.76	0.09
Total Long-Term Assets	5.76	5.67	6.46	6.73	0.45
Total Assets	95.94	126.41	78.67	104.69	5.2
Accounts Payable	1.28	1.69	1.66	2.63	3.54
Current Debt	0.84	0.61	0.59	0.52	0.1
Other Current Liabilities	7.39	8.41	6.59	5.84	2.26
Total Current Liabilities	9.51	10.71	8.85	8.99	5.9
Long-Term Debt	4.71	4.8	5.41	6	0
Total Long-Term Liabilities	4.71	4.8	5.41	6	0
Total Liabilities	14.22	15.5	14.25	14.99	5.9
Total Debt	5.55	5.41	6	6.52	0.1
Debt Growth	2.55%	-9.90%	-7.90%	6618.56%	-99.53%
Retained Earnings	-188.55	-151.61	-116.25	-65.61	-23.13
Comprehensive Income	0.08	-0.03	0	0	0
Shareholders' Equity	81.72	110.9	64.41	89.69	-0.69
Net Cash / Debt	82.58	114.36	65.43	87.46	0.91
Net Cash / Debt Growth	-27.79%	74.77%	-25.18%	9489.91%	-99.06%
Net Cash Per Share	1.88	4.44	3.81	7.36	0.15
Working Capital	80.67	110.03	63.36	88.96	-1.15
Book Value Per Share	1.86	4.30	3.75	7.55	-0.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).